Advertisement
Advertisement

CVM

CVM logo

Cel-Sci Corporation

1.70
USD
Sponsored
+0.10
+6.25%
May 08, 15:58 UTC -4
Closed
exchange

After-Market

1.69

-0.01
-0.88%

Cel-Sci Corporation Profile

About

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.

Info & Links

CEO

Geert Kersten

Headquarters

8229 BOONE BLVD ., SUITE 802
VIENNA, VA 22182, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.cel-sci.com

Auditor

BDO USA, P.C.

Share holders

425

Employees

--

Cel-Sci Corporation Statistics

Valuation Measures

Market Capitalization2

14.25M

Enterprise Value

15.39M

Enterprise Value/EBITDA(ttm)

-0.79

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

3.23

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-226.09%

Return on Invested Capital(ttm)

-148.81%

Return on Assets(ttm)

-102.18%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-19.43M

Net Income Available to Common(ttm)

-23.81M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

0.99

52-Week Change

-77.76%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

8.46M

Dividend Yield

0.00%

Float4

7.62M

% Held by Insiders

9.93%

% Held by Institutions

12.08%

Balance Sheet

Total Cash(mrq)

6.28M

Total Cash Per Share(mrq)

0.74

Total Debt(mrq)

7.41M

Total Debt/Equity(mrq)

66.55%

Current Ratio(mrq)

1.39%

Quick Ratio(mrq)

1.35%

Book Value Per Share(mrq)

1.32

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.50

Free Cash Flow(ytd)

-4.02M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement